Surgical Treatment for Refractory Drug Addiction




Abstract


Addiction is associated with enormous individual distress and tremendous socioeconomic consequences, and remains one of the most challenging health problems of today. Unfortunately, pharmacological, psychological, and social interventions often do not result in long-lasting remission. Attempts to treat addiction by performing psychosurgery have been made in the past, where lesions were created in specific brain circuits believed to be dysfunctional in addiction. Procedures including cingulotomy, hypothalamotomy, and ablation of the nucleus accumbens have been applied in the treatment of severe addictive disorders. Deep brain stimulation (DBS) is a powerful tool for modulating dysregulated networks that has demonstrated successful application and been granted approval for the treatment of several neurological disorders, and has also been considered for the treatment of substance addiction. Preliminary case reports of DBS for addiction in humans showing promise have recently been published. The objective of this chapter is to provide an overview of published results on psychosurgery in addiction, and discuss how these preliminary results justify further research.




Keywords

Addiction, Deep brain stimulation, Lateral habenular, Nucleus accumbens, Psychosurgery, Substance use disorder

 






  • Outline



  • Overview 1089



  • The Development of Stereotactic Surgery for Drug Addiction 1090



  • The Pathophysiology of Drug Addiction 1091



  • Neurosurgical Procedures 1093



  • Mechanisms 1093



  • Future Expectations 1094



  • Conclusions 1094



  • References 1095




Overview


Drug addiction is characterized by repetitive substance abuse associated with symptoms of behavioral, cognitive, and physiological dependence, and is categorized in the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) as “substance use disorder.” Dependence is indicated by a persistent desire to use the addictive substance, continuous reckless and uncontrollable usage, and the prioritization of drug abuse over other activities and obligations ( ). Drug abuse is a serious health problem that places a heavy burden to drug users and their families. It is estimated that approximately 250 million people worldwide abused illicit drugs in 2013, which corresponds to 5% of the population between 15 and 64 years of age. Approximately 10% of drug abusers suffer from drug addiction, of whom half are intravenous drug users, and more than 10% of the latter are HIV positive. According to a survey in 2015 there were 2.3 million drug users in China (excluding those with more than 3 years in remission). Among these there were 980,000 heroin and opiate users and 1.3 million synthetic drug users. Substance use disorder remains a major health problem in China and worldwide ( ).


Treatment for drug addiction typically falls into one of two categories: drug based or behavioral intervention. Drug-based treatment is centered on a replacement approach, in which molecules with similar pharmacological properties to the addictive substance but different pharmacokinetics are used to substitute the addictive substance. The aim of this approach is to reduce the amount of drug intake, with the application of methadone in opioid addiction representing the most common example of replacement therapy ( ). Behavioral interventions such as cognitive behavioral therapy ( ) and contingency management therapy ( ) serve to rebuild the cognitive function of drug-addicted individuals and reshape dysfunctional cognitive control. There is a distinction between two core symptom dimensions of drug addiction: physiological dependence (physical dependence) and psychological dependence (emotional dependence). Physiological dependence is related to withdrawal symptoms experienced physically, while psychological dependence pertains to emotional and motivational withdrawal ( ). The latter is often a key factor in unsuccessful treatment and addiction relapse, and presents a significant challenge to the medical field and society as a whole.


With the advancement of several pilot studies and stereotactic functional neurosurgery, it is now possible to reduce psychological dependence in drug addiction effectively using a minimally invasive surgical approach targeting specific brain nuclei to regulate underlying aberrant neural activity therapeutically. Stereotactic surgery is an important field in modern neurosurgery developed throughout decades of research in functional brain disorders, and has been employed in the treatment of movement disorders, psychiatric disorders, and chronic pain in cases refractory to noninvasive treatment methods ( ). Stereotactic surgery is mainly based on invasive surgery and the use of deep brain stimulation (DBS). The effectiveness of ablative stereotactic procedures in treating drug addiction has been recognized in several clinical studies in China ( ). In comparison, the reversibility and adjustability of stimulation parameters using DBS offers a considerable improvement in terms of patient experience during treatment and recovery. DBS is therefore a promising treatment option for intractable neurological disorders .




Figure 90.1


Electrode and stimulation program setting. The SceneRay 1242 electrode was designed to have a diameter of 1.27 mm and 4 contacts. The contact length is 3.0 mm and the spacing between the ventral and dorsal contacts is 2, 4, and 4 mm, with a total length of 22.5 mm (3+2+3+4+3+4+3 and 0.5 projecting from the electrode tip). The electrodes were designed to enable independently programmed stimulation after implantation, spanning from the anterior limb of the internal capsule (ALIC) to the nucleus accumbens (NAc), with two ventral contacts located within the ventral NAc and two dorsal contacts located within the ALIC. Copied from Lei Chen’s doctorial thesis with permission, Novel deep brain stimulation in ventral striatum/ventral capsule to treat opioid addiction (in Chinese).



Figure 90.2


Ventral capsule/ventral striatum deep brain stimulation magnetic resonance imaging.




The Development of Stereotactic Surgery for Drug Addiction


Stereotactic technology was initially applied in psychosurgery in the late 1950s to achieve accurate target positioning while minimizing incision size and reducing the incidence rate of postoperative complications. Neurosurgeons first attempted surgical treatment of substance addiction in the 1970s. In Müller et al. reported a case of successful treatment for alcohol addiction after performing stereotactic surgery on the unilateral ventromedial hypothalamus. Five years later Dieckmann and Schneider published treatment outcomes of 15 cases of stereotactic surgery on the hypothalamus of patients addicted to alcohol and drugs ( ). Due to the occurrence of adverse events, Dieckmann and Schneider considered limited applications for targeted surgical approaches in the treatment of addiction disorders. In Balasubramaniam et al. analyzed the treatment outcomes of 28 cases of addicted patients who had undergone bilateral stereotactic cingulotomy. This was the first case study examining the suitability of stereotactic cingulotomy to treat addiction. Five years later Kanaka and Balasubramaniam analyzed the treatment outcomes of 73 cases of addicted patients who underwent stereotactic cingulotomy ( ), reporting an outcome of 60%–80% effectiveness that was regarded as a highly promising for the therapeutic potential of surgical approaches for drug addiction. In Medvedev et al. studied the long-term impacts of cryogenic bilateral stereotactic cingulotomy performed on 348 heroin-dependent patients, reporting positive outcomes in 62% of cases .


In 2000 Gao et al. performed stereotactical surgery on the bilateral nucleus accumbens (NAc) to treat opiate addiction in 42 patients at Tangdu Hospital in Xi’an, China ( ). They reported positive outcomes in 45% patients, with these patients not experiencing addiction relapse 1 year after surgery, and a rare occurrence of adverse reactions ( ). A growing number of hospitals in China began to adopt stereotactic surgery, and the number of patients undergoing this procedure increased dramatically by 2004. Taking into consideration that stereotactic surgery is still in the clinical research stage, the unclear neural mechanism underlying drug addiction, possible but unpredictable long-term complications, and other factors, stereotactic operations were suspended by the Chinese Ministry of Health in November 2004, with their application limited to clinical research. Other countries including Russia also prohibited these procedures in 2002. Following the suspension of clinical applications of stereotactic surgery in China, the cessation rate was 50% in multicenter retrospective cohort studies after several years ( ).


DBS treatment for drug addiction has a shorter history ( Table 90.1 ), with research currently still in its preliminary stages. The nucleus accumbens (NAc or ventral striatum) is the most popular target.



Table 90.1

DBS Treatment for Addiction Summary












































































































Investigator Date N. Substance Device IPG Parameters Follow-Up Outcome Adverse Events
Bilateral NAc
Kuhn 2007 1 Alcohol Medtronic 3387 Monopolar 1−, 2−, C+, 130 Hz, 90 μs, 3–4.5 V 12 months Remission None
Muller 2009 3 Alcohol Medtronic 3387 Monopolar 0−, C+, 130 Hz, 90 μs, 3.5–4.5 V 12 months 2 cessation, 1 remission Transient reversible hypomania
Kuhn 2011 1 Alcohol Medtronic 3387 N/A 12 months Cessation None
Juergen Voges 2013 5 Alcohol Medtronic 3387 Bipolar with two dorsal contracts active, 130 Hz, 90 μs, 4.5 V ≥2.5 years 2 cessation, 3 remission Transient reversible hypomania
Mantione 2010 1 Nicotine Medtronic 3389 Monopolar 2–, 3–, C+, 185 Hz, 90 μs, 3.5 V 2 years Cessation None
Zhou 2011 1 Heroin Medtronic 3387 145 Hz, 90 μs, 2.5 V with stimulation on for 2 years 6 years Remission NA
Wang 2011 2 Heroin Medtronic 3387 Monopolar with 0–, 4–, case+, 145 Hz, 120 μs, 3.5 V NA 1 remission, 1 relapse Transient reversible hypomania
Bilateral/Unilateral VC/Ventral Striatum
Kuhn 2009 10 Nicotine Medtronic 3387 130/140/145 Hz, 90/180 μs, 3–6.5 V ≥2 years 3 unaided cessation NA
Valencia-Alfonso 2012 1 Heroin Medtronic 3387 Bipolar 2,3; 180 Hz, 90 μs, 3.5 V 6 months Remission NA

N. , number of patients; NA , not available; NAc , nucleus accumbens; VC , ventral capsule.


In accordance with the anatomical features of the ventral capsule/ventral striatum (VS), we developed a novel electrode (the Sceneray 1242) ( Fig. 90.1 ) for simultaneous and independently programmed stimulation of the NAc and the anterior limb of the internal capsule. The Fourth Military Medical University, Tang Du Hospital employed our adaptation of the Sceneray 1242 electrode in a prospective single-center nonrandom clinical trial ( clinicaltrials.gov NCT01274988 ). A total of eight cases with long-term (>3 years) opiate addiction (more than three unsuccessful cessation attempts) were recruited. Through standardized stereotactic surgery, electrodes were implanted into the NAc and anterior capsulotomy (ring angle, 68.3 ± 4.78 degrees and arc angle, 61 ± 3.25 degrees on the right side of the brain; 66.6 ± 4.1 degrees and 118.7 ± 2.67 degrees on the left side of the brain, with the stereotactic arc bow from a horizontal elevation forward 21–24 degrees and the midline 28–30 degrees) ( Fig. 90.2 ). Parameters were adjusted to be NAc target, 2–3 V, 180–240 μs, 145 Hz; anterior capsulotomy target 2–3 V, 120–210 μs, 185 Hz, wherein the uppermost contacts (3, 7) elicited a weak reaction. After 6 months of treatment and follow-up, seven patients reported significantly lower drug cravings. Six patients reported no relapse, reduced drug cravings, improvement in general mental state and depression, reduced obsessive–compulsive symptoms, and an increase in overall quality of life as well as good toleration of surgery. Based on these preliminary data, we are now recruiting patients in China for the first-ever randomized controlled trial investigating the effectiveness of DBS in the treatment of substance use disorder.




The Pathophysiology of Drug Addiction


The pathophysiological mechanisms of drug addiction are highly complex. Despite variations in chemical structure among addictive drugs and their different neuroanatomical and pharmacological effects, “reward” and “strengthening” are fundamental concepts in the pathophysiology of drug addiction. In recent years developments in neuroimaging have provided insight into the reward system and its dysfunction in addicted patients. The neuroanatomical features of the reward system consist mainly of the anterior cingulate, orbitofrontal cortex, and ventral striatum (VS); the latter includes the NAc and ventral tegmental area (VTA) ( ). The ventral pallidum, dorsomedial hypothalamic nucleus, amygdala, hippocampus, lateral habenula, pedunculopotine tegmental nucleus, and raphe nucleus also exhibit regulatory effects on the reward system ( ). Furthermore, the NAc/VS is considered in neuroanatomy as the limbic–motor interface, where neural “motivation” is translated into “action” ( ).


The NAc receives dopaminergic neural inputs from the VTA. When these neurons are excited by rewarding stimuli, such as success, attention, food, or sexual activation (in gradual or abrupt stages), dopamine release by NAc increases. In addition, when one is expecting a reward these neurons are activated to produce “motivation” to participate in activities to ensure the reward ( ). The focal development of drug addiction is repeated exposure to similar stimulation, which results in reduced dopamine release and reactivity ( ). The functions of the reward system may be weakened by drug (such as heroin) abuse, as dopamine release is reduced in varying degrees during repeated exposures ( ). Due to NAc dopamine’s activation of conditional behaviors and recognition of behavioral responses, differentiated coding of NAc dopaminergic neurons generates goal-oriented behaviors for drug (such as cocaine) and natural (such as food) rewards ( ). Hence NAc dopamine change may play a key role in drug addiction: the hypofunction of the mesolimbic dopamine system of the addicted brain results in reduced reaction to nondrug-related stimulation and increased sensitivity to drugs ( ).


Addiction patients’ NAc/VS regulatory function relies on proper balance, sequential activation of the NAc’s medium spiny neuron D 1 and D 2 receptors ( ), and D 1 -assisted N-methyl- d -aspartate receptor coactivation, indicating the importance of glutamatergic systems in reinforcement learning response ( ). Psychoactive substances such as alcohol may interfere with this delicate interaction ( ). Rapid cocaine exposure is associated with D 1 -expressing NAc neurons and their synaptic plasticity ( ). Rapid modification of D 1 receptor expression constantly changes the D 1 😀 2 ratio ( ), causing imbalanced competitive influences of the prefrontal lobe and limbic lobe, which manifests in addiction patients as compulsion and executive dysfunction ( ). Rewarding substances cause addicted individuals to become sensitive to drugs and drug-related cues via involvement in incentive motivation brain circuits, so they shift from “liking” to “desiring” drugs, causing compulsive drug-seeking behaviors ( ). A study with functional magnetic resonance imaging (MRI) has demonstrated that addicted individuals pay significantly increased attention to drug-related cues in comparison to neutral cues ( ).

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Sep 9, 2018 | Posted by in NEUROLOGY | Comments Off on Surgical Treatment for Refractory Drug Addiction

Full access? Get Clinical Tree

Get Clinical Tree app for offline access